Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-09-02
2008-11-18
Belyavskyi, Michail (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S154100
Reexamination Certificate
active
07452981
ABSTRACT:
A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
REFERENCES:
patent: 5777085 (1998-07-01), Co et al.
patent: 1 241 249 (2002-09-01), None
patent: WO 91/09966 (1991-07-01), None
Racadot et. al. Immunological follow-up of 17 patients with rheumatoid arthritis treated in vivo with an anti-T CD4+ monoclonal antibody (B-F5). Clinical and Experimental Rheumatology. 1992; 10: 365-374.
Rudikoff et. al. Single amino acid substitution altering antigen-binding specificity. Proc. Natl. Acad. Sci. 1982; 79: 1979-1983.
Panka et. al. Variable region framework differences results in decreased or increased affinity of variant anti-digoxin antibodies. Proc. Natl. Acad. Sci. 1988; 85: 3080-3084.
Bartholomew, M.; et al., “Functional analysis of the effects of a fully humanized anti-CD4 antibody on resting and activated human T cells,” Immunology 1995;85(1):41-48.
Racadot, E., et al., “Immunological follow-up of 17 patients with rheumatoid arthritis treated in vivo with an anti-T CD4+ monoclonal antibody (B-F5),” Clin. Exp. Rheumatol. 1992;10:365-374.
International Search Report for PCT/EP2004/002888 (Aug. 5, 2004).
International Preliminary Examination Report for PCT/EP2004/002888 (Jan. 12, 2005).
Boshart, M., et al., “A Very Strong Enhancer Is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus,” Cell 1985;41:512-530.
Canva-Delcambre, V., et al., “Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody,” Aliment. Pharmacol. Ther. 1996;10:721-727.
Chothia, C., et al., “Conformation of immunoglobulin hypervariable regions,” Nature 1989;342:877-883.
Chothia, C., et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol. 1987;196:901-917.
Cohen, J. L., et al., “CD4+CD25+Immunoregulatory T Cells: New Therapeutics for Draft-Versus-Host Disease,” J. Exp. Med. 2002;196(3):401-406.
Coloma, M. J., et al., “Primer Design for the Cloning of Immunoglobulin Heavy-Chain Leader-Variable Regions from Mouse Hybridoma Cells Using the PCR,” BioTechniques 1991;11(2):152-156.
Dantal, J., et al., “Anti-CD4 MoAb Therapy in Kidney Transplantation—A Pilot Study in Early Prophylaxis of Rejection,” Transplantation 1996;62(10):1502-1506.
Darby, C. R., et al., “Nondepleting Anti-CD4 Antibodies in Transplantation,” Transplant. 1994;57(10):1419-1426.
Dieckmann, D., et al., “Ex Vivo Isolation and Characterization of CD4+CD25+T cells with Regulatory Properties from Human Blood,” J. Exp. Med. 2001;193(11):1303-1310.
Edmundson, A. B., et al., “A Search for Site-Filling Ligands in the Mcg Bence-Jones Dimer: Crystal Binding Studies of Fluorescent Compounds,” Mol. Immunol. 1984;21(7):561-576.
Felgner, P. L., et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,” Proc. Natl. Acad. Sci. USA 1987;84:6413-7417.
Foote, J., et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,” J. Mol. Biol. 1992;224:487-499.
Gillies, S. D., et al., “A Tissue-specific Transcription Enhancer Element Is Located in the Major Intron of a Rearranged Immunoglobulin Heavy Chain Gene,” Cell 1983;33:717-728.
Goetzl, E. J., et al., “Affinity Labeling of a Mouse Myeloma Protein Which Binds Nitrophenyl Ligands. Kinetics of Labeling and Isolation of a Labeled Peptide,” Biochemistry 1970;9(5):1267-1278.
Goldberg, D., et al., “Immunological Effects of High Dose Administration of Anti-CD4 Antibody in Rheumatoid Arthritis Patients,” J. Autoimmun. 1991;4:617-630.
Gorman, C. M., et al., “The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection,” Proc. Natl. Acad. Sci. USA 1982;79:6777-6781.
Gorman, S. D., et al., “Reshaping a therapeutic CD4 antibody,” Proc. Natl. Acad. Sci. USA 1991;88:4181-4185.
Gottlieb, A. B., et al., “Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose placebo-controlled study,” J. Am. Acad. Dermatol. 2000;43:595-604.
Graham, F. L., et al., “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA,” Virology 1973;52:456-467.
Hoffmann, P., et al., “Donor-type CD4+CD25+Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogenic Bone Marrow Transplantation,” J. Exp. Med. 2002;196(3):389-399.
Jonuleit, H., et al., “Identification and Functional Characterization of Human CD4+CD25+T Cells with Regulatory Properties Isolated from Peripheral Blood,” J. Exp. Med. 2001;193(11):1285-1294.
Kabat, E. A., “Structure and Heterogeneity of Antibodies,” Proc. 10thCongr. Eur. Soc. Haematl., Strasbourg Acta haemat. 1966;36:198-238.
Kettleborough, C. A., et al., “Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation,” Protein Eng. 1991;4(7):773-783.
Levings, M. K., et al., “Human CD4+CD25+T Regulatory Cells Suppress Naïve and Memory T Cell Proliferation and Can Be Expanded In Vitro without Loss of Function,” J. Exp. Med. 2001;193(11):1295-1301.
Lusky, M., et al., “Inhibition of SV40 replication in simian cells by specific pBR322 DNA sequences,” Nature 1981;293:79-81.
Morel, P., et al., “Anti-CD4 Monoclonal Antibody Administration in Renal Transplanted Patients,” Clin. Immunol. Immunopath. 1990;56:311-322.
Morel, P., et al., “Anti-CD4 Monoclonal Antibody Therapy in Severe Psoriasis,” J. Autoimmun. 1992;5:465-477.
Mount, D. W., et al., “Microcomputer programs for back translation of protein to DNA sequences and analysis of ambiguous DNA sequences,” Nucl. Acids Res. 1984;21(1):819-823.
Orlandi, R., et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction,” Proc. Natl. Acad. Sci. USA 1989;86:3833-3837.
Osterburg, G., et al., “Computer programs for the analysis and the management of DNA sequences,” Nucl. Acids Res. 1982;10(1):207-216.
Potter, H., et al., “Enhancer-dependent expression of human κ immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation,” Proc. Natl. Acad. Sci. USA 1984;81:7161-7165.
Puls, R. L., et al., “Gene transfer and expression of a non-viral polycation-based vector in CD4+cells,” Gene Ther. 1999;6:1774-1778.
Racadot, E., et al., “Treatment of Multiple Sclerosis with Anti-CD4 Monoclonal Antibody,” J. Autoimmun. 1993;6:771-786.
Reczko, M., et al., “Prediction of hypervariable CDR-H3 loop structures in antibodies,” Protein Eng. 1995;8(4):389-395.
Rep. M. H. G., et al., “Treatment with Depleting CD4 Monoclonal Antibody Results in a Preferential Loss of Circulating Naïve T Cells but Does Not Affect IFN-γ Secreting TH1 Cells in Humans,” J. Clin. Invest. 1997;99(9):2225-2231.
Rumbach, L., et al., “Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients,” Multiple Sclerosis 1996;1:207-212.
Saitovitch, D., et al., “Kinetics of Induction of Transplantation Tolerance With a Nondepleting Anti-Cd4 Monoclonal Antibody and Donor-Specific Transfusion Before Transplantation: A Critical Period of Time Is Required for Development of Immunological Unresponsiveness,” Transplant. 1996;61(11):1642-1647.
Sakaguchi, S., et al., “Immunologic Self-Tolerance Maintained by Activated T Cells Expressing IL-2 Receptor α-Chains (CD25),” J. Immunol. 1995;155:1151-1164.
Sastry, L., et al., “Cloning of the immunological repertoire inEs
Jonuleit Helmut
Wijdenes John
Belyavskyi Michail
Biotest AG
Cermak Shelly Guest
Cermak Kenealy & Vaidya LLP
Skelding Zachary
LandOfFree
Humanized anti-CD4 antibody with immunosuppressive properties does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized anti-CD4 antibody with immunosuppressive properties, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-CD4 antibody with immunosuppressive properties will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4033908